Regeneron Pharmaceuticals, Inc. (0R2M.L)
USD 732.14
(-1.06%)
USD 732.14
(-1.06%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 3.95 Billion USD | -8.87% |
| 2022 | 4.33 Billion USD | -46.28% |
| 2021 | 8.07 Billion USD | 129.86% |
| 2020 | 3.51 Billion USD | 66.05% |
| 2019 | 2.11 Billion USD | -13.44% |
| 2018 | 2.44 Billion USD | 103.95% |
| 2017 | 1.19 Billion USD | 33.83% |
| 2016 | 895.52 Million USD | 40.79% |
| 2015 | 636.05 Million USD | 82.74% |
| 2014 | 348.07 Million USD | -17.98% |
| 2013 | 424.36 Million USD | -43.44% |
| 2012 | 750.26 Million USD | 438.32% |
| 2011 | -221.76 Million USD | -112.28% |
| 2010 | -104.46 Million USD | -54.01% |
| 2009 | -67.83 Million USD | 17.99% |
| 2008 | -82.71 Million USD | 21.68% |
| 2007 | -105.6 Million USD | -3.19% |
| 2006 | -102.33 Million USD | -7.22% |
| 2005 | -95.44 Million USD | -328.89% |
| 2004 | 41.69 Million USD | 138.8% |
| 2003 | -107.45 Million USD | 13.6% |
| 2002 | -124.37 Million USD | -63.27% |
| 2001 | -76.18 Million USD | -228.15% |
| 2000 | -23.21 Million USD | -0.5% |
| 1999 | -23.1 Million USD | -168.6% |
| 1998 | -8.6 Million USD | 25.86% |
| 1997 | -11.6 Million USD | 64.2% |
| 1996 | -32.4 Million USD | -37.87% |
| 1995 | -23.5 Million USD | 23.45% |
| 1994 | -30.7 Million USD | 23.06% |
| 1993 | -39.9 Million USD | -108.9% |
| 1992 | -19.1 Million USD | -324.44% |
| 1991 | -4.5 Million USD | -36.36% |
| 1990 | -3.3 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 1.43 Billion USD | 98.38% |
| 2024 Q1 | 722 Million USD | -37.74% |
| 2024 Q3 | 1.34 Billion USD | -6.4% |
| 2023 Q3 | 1 Billion USD | 4.07% |
| 2023 FY | 3.95 Billion USD | -8.87% |
| 2023 Q2 | 968.4 Million USD | 18.42% |
| 2023 Q1 | 817.8 Million USD | -31.68% |
| 2023 Q4 | 1.15 Billion USD | 15.06% |
| 2022 Q4 | 1.19 Billion USD | -9.01% |
| 2022 Q2 | 852.1 Million USD | -12.47% |
| 2022 Q1 | 973.5 Million USD | -56.33% |
| 2022 Q3 | 1.31 Billion USD | 54.41% |
| 2022 FY | 4.33 Billion USD | -46.28% |
| 2021 Q1 | 1.11 Billion USD | -2.96% |
| 2021 Q3 | 1.63 Billion USD | -47.33% |
| 2021 Q4 | 2.22 Billion USD | 36.56% |
| 2021 FY | 8.07 Billion USD | 129.86% |
| 2021 Q2 | 3.09 Billion USD | 177.88% |
| 2020 Q3 | 842.1 Million USD | -6.15% |
| 2020 FY | 3.51 Billion USD | 66.05% |
| 2020 Q2 | 897.3 Million USD | 43.66% |
| 2020 Q1 | 624.6 Million USD | -21.14% |
| 2020 Q4 | 1.14 Billion USD | 36.47% |
| 2019 FY | 2.11 Billion USD | -13.44% |
| 2019 Q4 | 792 Million USD | 18.28% |
| 2019 Q3 | 669.6 Million USD | 246.76% |
| 2019 Q2 | 193.1 Million USD | -58.12% |
| 2019 Q1 | 461.1 Million USD | -43.8% |
| 2018 Q4 | 820.4 Million USD | 37.96% |
| 2018 FY | 2.44 Billion USD | 103.95% |
| 2018 Q3 | 594.65 Million USD | 7.84% |
| 2018 Q2 | 551.41 Million USD | 15.36% |
| 2018 Q1 | 477.98 Million USD | 175.46% |
| 2017 Q1 | 248.93 Million USD | -1.65% |
| 2017 FY | 1.19 Billion USD | 33.83% |
| 2017 Q3 | 388.31 Million USD | 0.15% |
| 2017 Q4 | 173.51 Million USD | -55.32% |
| 2017 Q2 | 387.74 Million USD | 55.76% |
| 2016 Q4 | 253.11 Million USD | -4.41% |
| 2016 Q1 | 165.73 Million USD | 6.93% |
| 2016 Q2 | 196.21 Million USD | 18.39% |
| 2016 FY | 895.52 Million USD | 40.79% |
| 2016 Q3 | 264.8 Million USD | 34.95% |
| 2015 Q3 | 210.39 Million USD | 8.09% |
| 2015 FY | 636.05 Million USD | 82.74% |
| 2015 Q1 | 76.02 Million USD | -31.0% |
| 2015 Q2 | 194.64 Million USD | 156.04% |
| 2015 Q4 | 154.99 Million USD | -26.33% |
| 2014 Q4 | 110.17 Million USD | 38.2% |
| 2014 FY | 348.07 Million USD | -17.98% |
| 2014 Q1 | 65.44 Million USD | -32.4% |
| 2014 Q2 | 92.73 Million USD | 41.7% |
| 2014 Q3 | 79.72 Million USD | -14.03% |
| 2013 Q4 | 96.8 Million USD | -31.49% |
| 2013 FY | 424.36 Million USD | -43.44% |
| 2013 Q3 | 141.3 Million USD | 61.72% |
| 2013 Q2 | 87.37 Million USD | -11.63% |
| 2013 Q1 | 98.87 Million USD | -78.98% |
| 2012 FY | 750.26 Million USD | 438.32% |
| 2012 Q4 | 470.4 Million USD | 145.68% |
| 2012 Q1 | 11.65 Million USD | 121.8% |
| 2012 Q2 | 76.74 Million USD | 558.68% |
| 2012 Q3 | 191.46 Million USD | 149.49% |
| 2011 Q1 | -43.44 Million USD | -197.64% |
| 2011 Q4 | -53.44 Million USD | 14.31% |
| 2011 Q2 | -62.5 Million USD | -43.86% |
| 2011 FY | -221.76 Million USD | -112.28% |
| 2011 Q3 | -62.36 Million USD | 0.22% |
| 2010 Q2 | -25.47 Million USD | 16.54% |
| 2010 FY | -104.46 Million USD | -54.01% |
| 2010 Q3 | -33.87 Million USD | -32.98% |
| 2010 Q4 | -14.59 Million USD | 56.91% |
| 2010 Q1 | -30.52 Million USD | 16.35% |
| 2009 Q1 | -17.48 Million USD | 44.54% |
| 2009 Q2 | -14.93 Million USD | 14.55% |
| 2009 Q3 | -1.01 Million USD | 93.21% |
| 2009 Q4 | -36.48 Million USD | -3494.98% |
| 2009 FY | -67.83 Million USD | 17.99% |
| 2008 FY | -82.71 Million USD | 21.68% |
| 2008 Q4 | -31.51 Million USD | -49.27% |
| 2008 Q3 | -21.11 Million USD | -14.39% |
| 2008 Q2 | -18.45 Million USD | -58.88% |
| 2008 Q1 | -11.61 Million USD | 11.12% |
| 2007 Q3 | -35.83 Million USD | -33.85% |
| 2007 Q4 | -13.07 Million USD | 63.53% |
| 2007 FY | -105.6 Million USD | -3.19% |
| 2007 Q2 | -26.77 Million USD | 10.51% |
| 2007 Q1 | -29.91 Million USD | 3.4% |
| 2006 Q4 | -30.97 Million USD | -12.99% |
| 2006 FY | -102.33 Million USD | -7.22% |
| 2006 Q3 | -27.41 Million USD | -16.26% |
| 2006 Q2 | -23.57 Million USD | -15.68% |
| 2006 Q1 | -20.38 Million USD | 31.32% |
| 2005 Q3 | -34.65 Million USD | -28.35% |
| 2005 FY | -95.44 Million USD | -328.89% |
| 2005 Q2 | -26.99 Million USD | -554.84% |
| 2005 Q1 | -4.12 Million USD | -247.67% |
| 2005 Q4 | -29.67 Million USD | 14.37% |
| 2004 Q1 | 64.53 Million USD | 433.03% |
| 2004 FY | 41.69 Million USD | 138.8% |
| 2004 Q4 | 2.79 Million USD | 125.21% |
| 2004 Q3 | -11.07 Million USD | 23.87% |
| 2004 Q2 | -14.54 Million USD | -122.55% |
| 2003 Q2 | -28.73 Million USD | 4.56% |
| 2003 Q4 | -19.37 Million USD | 29.28% |
| 2003 FY | -107.45 Million USD | 13.6% |
| 2003 Q3 | -27.4 Million USD | 4.65% |
| 2003 Q1 | -30.11 Million USD | 15.64% |
| 2002 Q2 | -30.42 Million USD | -19.56% |
| 2002 Q1 | -25.44 Million USD | 10.34% |
| 2002 Q3 | -32.81 Million USD | -7.87% |
| 2002 Q4 | -35.69 Million USD | -8.77% |
| 2002 FY | -124.37 Million USD | -63.27% |
| 2001 Q3 | -19.93 Million USD | -34.36% |
| 2001 FY | -76.18 Million USD | -228.15% |
| 2001 Q1 | -13.03 Million USD | -33.86% |
| 2001 Q2 | -14.83 Million USD | -13.78% |
| 2001 Q4 | -28.37 Million USD | -42.38% |
| 2000 Q3 | -3.21 Million USD | -8.96% |
| 2000 Q2 | -2.94 Million USD | 59.73% |
| 2000 FY | -23.21 Million USD | -0.5% |
| 2000 Q1 | -7.31 Million USD | -422.71% |
| 2000 Q4 | -9.73 Million USD | -203.3% |
| 1999 Q1 | -8.9 Million USD | -61.82% |
| 1999 FY | -23.1 Million USD | -168.6% |
| 1999 Q4 | -1.4 Million USD | 71.43% |
| 1999 Q3 | -4.9 Million USD | 37.18% |
| 1999 Q2 | -7.8 Million USD | 12.36% |
| 1998 FY | -8.6 Million USD | 25.86% |
| 1998 Q3 | -1.4 Million USD | -166.67% |
| 1998 Q4 | -5.5 Million USD | -292.86% |
| 1998 Q1 | -3.8 Million USD | -860.0% |
| 1998 Q2 | 2.1 Million USD | 155.26% |
| 1997 Q3 | -1.9 Million USD | 55.81% |
| 1997 Q1 | -5.9 Million USD | 27.16% |
| 1997 FY | -11.6 Million USD | 64.2% |
| 1997 Q4 | 500 Thousand USD | 126.32% |
| 1997 Q2 | -4.3 Million USD | 27.12% |
| 1996 Q2 | -7.6 Million USD | 2.56% |
| 1996 Q4 | -8.1 Million USD | 8.99% |
| 1996 Q1 | -7.8 Million USD | 0.0% |
| 1996 FY | -32.4 Million USD | -37.87% |
| 1996 Q3 | -8.9 Million USD | -17.11% |
| 1995 FY | -23.5 Million USD | 23.45% |
| 1995 Q4 | -7.8 Million USD | -9.86% |
| 1995 Q3 | -7.1 Million USD | -61.36% |
| 1995 Q2 | -4.4 Million USD | -4.76% |
| 1995 Q1 | -4.2 Million USD | 27.59% |
| 1994 Q2 | -10.2 Million USD | 4.67% |
| 1994 Q4 | -5.8 Million USD | -45.0% |
| 1994 FY | -30.7 Million USD | 23.06% |
| 1994 Q3 | -4 Million USD | 60.78% |
| 1994 Q1 | -10.7 Million USD | 6.96% |
| 1993 Q2 | -9.4 Million USD | -1.08% |
| 1993 Q4 | -11.5 Million USD | -19.79% |
| 1993 Q3 | -9.6 Million USD | -2.13% |
| 1993 FY | -39.9 Million USD | -108.9% |
| 1993 Q1 | -9.3 Million USD | -45.31% |
| 1992 Q3 | -5.8 Million USD | -56.76% |
| 1992 Q1 | -3.3 Million USD | -57.14% |
| 1992 FY | -19.1 Million USD | -324.44% |
| 1992 Q4 | -6.4 Million USD | -10.34% |
| 1992 Q2 | -3.7 Million USD | -12.12% |
| 1991 Q1 | - USD | 0.0% |
| 1991 Q3 | -900 Thousand USD | -200.0% |
| 1991 Q4 | -2.1 Million USD | -133.33% |
| 1991 FY | -4.5 Million USD | -36.36% |
| 1991 Q2 | -300 Thousand USD | 0.0% |
| 1990 Q1 | - USD | 0.0% |
| 1990 FY | -3.3 Million USD | 0.0% |
| 1990 Q4 | - USD | 0.0% |
| 1990 Q3 | - USD | 0.0% |
| 1990 Q2 | - USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -153.21 Million USD | 2680.359% |
| Dynavax Technologies Corporation | -6.38 Million USD | 61981.359% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | -300325.532% |
| Perrigo Company plc | -12.7 Million USD | 31230.709% |
| Illumina, Inc. | -1.16 Billion USD | 440.534% |
| Thermo Fisher Scientific Inc. | 5.99 Billion USD | 34.052% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 990.376% |
| Walgreens Boots Alliance, Inc. | -8.63 Billion USD | 145.78% |
| IQVIA Holdings Inc. | 1.35 Billion USD | -191.134% |
| Heron Therapeutics, Inc. | -110.55 Million USD | 3676.009% |
| Unity Biotechnology, Inc. | -39.86 Million USD | 10018.716% |
| Waters Corporation | 642.23 Million USD | -515.601% |
| Biogen Inc. | 1.16 Billion USD | -240.505% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 1633.408% |
| Evolus, Inc. | -61.68 Million USD | 6509.338% |
| Adicet Bio, Inc. | -142.65 Million USD | 2871.383% |
| Cara Therapeutics, Inc. | -118.51 Million USD | 3436.005% |
| bluebird bio, Inc. | -211.91 Million USD | 1965.671% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 1989.433% |
| FibroGen, Inc. | -284.23 Million USD | 1490.976% |
| Agilent Technologies, Inc. | 1.24 Billion USD | -218.839% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | 8963.915% |
| Homology Medicines, Inc. | -53.74 Million USD | 7456.493% |
| Geron Corporation | -184.12 Million USD | 2247.214% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 998.052% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | 2708.191% |
| Myriad Genetics, Inc. | -112 Million USD | 3630.0% |
| Viking Therapeutics, Inc. | -85.89 Million USD | 4702.829% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 921.626% |
| Zoetis Inc. | 2.34 Billion USD | -68.669% |
| Abeona Therapeutics Inc. | -54.18 Million USD | 7396.08% |
| Mettler-Toledo International Inc. | 788.77 Million USD | -401.231% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | -2258.317% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | -9.228% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 9468.942% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 1179.375% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 1531.81% |
| Verastem, Inc. | -87.36 Million USD | 4625.278% |
| Nektar Therapeutics | -276.05 Million USD | 1532.173% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 1752.58% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | 4568.304% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 837.644% |
| OPKO Health, Inc. | -188.86 Million USD | 2193.369% |
| Exelixis, Inc. | 207.76 Million USD | -1802.919% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | -1483.34% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | -3624.892% |
| Anavex Life Sciences Corp. | -47.5 Million USD | 8422.492% |
| uniQure N.V. | -308.47 Million USD | 1381.647% |
| Imunon, Inc. | -19.51 Million USD | 20359.312% |
| Blueprint Medicines Corporation | -506.98 Million USD | 879.827% |
| Insmed Incorporated | -749.56 Million USD | 627.451% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | -1304.007% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 1222.901% |
| TG Therapeutics, Inc. | 12.67 Million USD | -31099.495% |
| Incyte Corporation | 597.59 Million USD | -561.581% |
| Emergent BioSolutions Inc. | -760.5 Million USD | 619.869% |